In addition, combination therapy involving the depletion of extracellular asparagine (e.g., ASNase) and AKT inhibition decreased tumor growth, suggesting that ASNS can be a promising therapeutic target for KRAS-driven NSCLC [50]. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.